TIDMDXRX
RNS Number : 0347A
Diaceutics PLC
19 May 2023
19 May 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical industry, announces the issue of
1,276,707 share options over ordinary shares of GBP0.002 each in
the Company ("Share Options") to certain directors, members of the
Company's senior management team and other key staff, pursuant to
the Company's Employee Share Option Plan ("ESOP"). These awards are
made in accordance with the Company's long term incentive plan as
detailed in the Company's Annual Report.
Share Options were granted as follows:
Name Number of Total no. of % of existing Effective
Share Options ordinary shares issued share Grant date
granted under option post capital
grant
Peter Keeling, CEO 102,468 435,313 0.52% 18 May 2023
-------------- ------------------ ------------- -----------
Nick Roberts, CFO 67,034 158,872 0.19% 18 May 2023
-------------- ------------------ ------------- -----------
Ryan Keeling, CIO 93,407 409,851 0.49% 18 May 2023
-------------- ------------------ ------------- -----------
Julie Browne, COO
and PDMR 67,109 169,047 0.20% 18 May 2023
-------------- ------------------ ------------- -----------
Jordan Clark, CCO
and PDMR 65,245 115,740 0.14% 18 May 2023
-------------- ------------------ ------------- -----------
Susanne Munksted,
CPO and PDMR 68,834 249,199 0.30% 18 May 2023
-------------- ------------------ ------------- -----------
Other employees
(43 persons) 812,610 1,675,537 1.98% 18 May 2023
-------------- ------------------ ------------- -----------
The Share Options vest on a sliding scale up to 100%, after
three years from the date of grant (the "Performance Period"),
subject to the satisfaction of certain performance criteria. The
performance criteria are based upon the growth in the proportion of
subscription revenue and Total Shareholder Return ("TSR") during
the Performance Period. The growth in TSR will be measured against
a base share price of 103.97p, being the average mid-market closing
share price in the three days prior to 18 May 2023. The exercise
price of the Share Options is GBP0.002 per share which equates to
the nominal value of the ordinary shares.
Following this grant, the total number of share options
outstanding in the Company is 3,826,487 representing approximately
4.52% of its current issued share capital of 84,461,386.
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Via Alma PR
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison, Nick Harland, Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde, Kieran Breheny, Matthew Young diaceutics@almapr.co.uk
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome. We provide the world's
leading pharmaceutical and life science companies with solutions
and technology for the commercialisation of their precision
medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, utilising a global network of affiliate
laboratories to deliver multiple pipelines of real--world
healthcare data insights, advisory services and innovative platform
enabled solutions.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------
a. Name Peter Keeling
-----------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------
a. Position/Status Chief Executive Officer, Director
------------------------------------- -----------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 102,468
---------------------------------------------------------------------- ---------------
e. Date of the transaction 18 May 2023
------------------------------------- -----------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------
a. Name Nick Roberts
-----------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------
a. Position/Status Chief Finance Officer, Director
------------------------------------- -----------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 67,034
---------------------------------------------------------------------- ---------------
e. Date of the transaction 18 May 2023
------------------------------------- -----------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------
a. Name Ryan Keeling
-----------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------
a. Position/Status Chief Innovation Officer , Director
------------------------------------- -----------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 93,407
---------------------------------------------------------------------- ---------------
e. Date of the transaction 18 May 2023
------------------------------------- -----------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------
a. Name Julie Browne
-----------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------
a. Position/Status Chief Operations Officer and PDMR
------------------------------------- -----------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 67,109
---------------------------------------------------------------------- ---------------
e. Date of the transaction 18 May 2023
------------------------------------- -----------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------------
a. Name Jordan Clark
-----------------------------------------------
2 Reason for notification
------------------------------------- -----------------------------------------------
a. Position/Status Chief Commercial Officer and PDMR
------------------------------------- -----------------------------------------------
b. Initial notification/ Initial
Amendment
-----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -----------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -----------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 65,245
---------------------------------------------------------------------- ---------------
e. Date of the transaction 18 May 2023
------------------------------------- -----------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -----------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ----------------------------------------------------------------------------------------
a. Name Susanne Munksted
-------------------------------------------------
2 Reason for notification
------------------------------------- -------------------------------------------------
a. Position/Status Chief Precision Medicine Officer and PDMR
------------------------------------- -------------------------------------------------
b. Initial notification/ Initial
Amendment
-------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ----------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- -------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- -------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- ---------------------------
Exercise price
of 0.2p per
share 68,834
----------------------------------------------------------------------- ----------------
e. Date of the transaction 18 May 2023
------------------------------------- -------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- -------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHKKLBFXELFBBZ
(END) Dow Jones Newswires
May 19, 2023 05:16 ET (09:16 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024
